Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Chosa Oncology AB is a biopharmaceutical company primarily focused on the development and commercialization of innovative cancer therapies. Central to its mission is the discovery and advancement of treatments designed to target specific cancer pathways, tailored for precision oncology. The company engages in comprehensive research and development activities, translating scientific advancements into effective therapeutic solutions aimed at improving patient outcomes. Operating in the dynamic and highly specialized field of oncology, Chosa Oncology AB collaborates with leading research institutions and industry partners to harness cutting-edge technologies and medical insights. Its market role is significant, as it contributes to the growing arsenal of cancer treatments, addressing unmet medical needs and fostering advances that positively impact public health. Through its dedicated efforts, Chosa Oncology AB plays a pivotal role in enhancing the life expectancy and quality of life for cancer patients worldwide.
kr 0.07
+kr 0.00 (+6.83%)
EOD Jun 23, 2026 · Twelve Data
Negative free cash flow of -kr 9M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 1M
▲ +41.5% YoY
Op. Margin
—
ROIC
-32.43%
▲ +16.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 9M
▼ -9.7% YoY
Op. Cash Flow (TTM)
-kr 41K
▲ +40.6% YoY
Net Debt
-kr 2M
Net Cash Position
Cash & Equiv.
kr 2M
Continue Research
Chosa Oncology AB (CHOSA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Chosa Oncology AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Chosa Oncology AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -32.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CHOSA.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.